X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.
Lead Product(s): Cefuroxime Axetil
Therapeutic Area: Infections and Infectious Diseases Product Name: Zinnat
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 11, 2021
Details:
Cephalosporin manufacturing will transfer from GSK sites to Sandoz following a four-year manufacturing and supply agreement (MSA) and subsequent transfer of manufacturing operations.
Lead Product(s): Cefuroxime Axetil
Therapeutic Area: Infections and Infectious Diseases Product Name: Zinnat
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Divestment February 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
